Related Experiment Videos
Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease.
Angela Rampa1, Manuela Bartolini2, Letizia Pruccoli3
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. angela.rampa@unibo.it.
Molecules (Basel, Switzerland)
|August 1, 2018
Summary
New chalcone derivatives show promise for Alzheimer's disease treatment by inhibiting cholinesterases and providing antioxidant and neuroprotective effects. Compound 4 demonstrates significant potential by targeting key pathways involved in disease progression.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) lacks effective treatments, necessitating novel therapeutic strategies.
- Cholinesterase inhibitors targeting acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are a focus for AD drug development.
- Chalcone derivatives offer a versatile scaffold for designing multi-target agents.
Purpose of the Study:
- To design and synthesize novel chalcone-based compounds as potential Alzheimer's disease therapeutics.
- To evaluate the synthesized compounds for dual AChE and BuChE inhibitory activity.
- To assess the antioxidant and neuroprotective properties of these compounds in a cellular model.
Main Methods:
- Synthesis of a series of chalcone derivatives inspired by a previous benzofuran lead compound.
- In vitro evaluation of cholinesterase inhibition against human AChE and BuChE.
- Assessment of antioxidant activity (ROS reduction, GSH level increase) and neuroprotection in a SH-SY5Y cell line challenged with Aβ₁₋₄₂ oligomers.
Main Results:
- Most synthesized chalcone derivatives exhibited low micromolar inhibitory activity against AChE and/or BuChE.
- Compounds displayed varying selectivity profiles for AChE versus BuChE inhibition.
- Several compounds demonstrated significant antioxidant and neuroprotective effects.
- Compound 4 showed dual AChE/BuChE inhibition, reduced reactive oxygen species (ROS), increased glutathione (GSH) levels, and protected against Aβ₁₋₄₂-induced neurotoxicity.
Conclusions:
- Chalcone derivatives represent a promising class of compounds for Alzheimer's disease therapy.
- Compound 4 exhibits multi-faceted therapeutic potential, including cholinesterase inhibition, enhanced endogenous antioxidant defense, and neuroprotection.
- Further investigation of compound 4 is warranted for its development as a potential Alzheimer's disease drug.